Here's Why We Think CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Looks Fair for the Time Being
Here's Why We Think CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Looks Fair for the Time Being
Key Insights
主要見解
- CorMedix to hold its Annual General Meeting on 21st of November
- Total pay for CEO Joe Todisco includes US$617.0k salary
- The overall pay is comparable to the industry average
- CorMedix's total shareholder return over the past three years was 124% while its EPS was down 7.3% over the past three years
- cormedix將在11月21日召開年度股東大會
- CEO Joe Todisco的總薪酬包括61.7萬美元的工資
- 總報酬數與行業平均水平相當。
- cormedix過去三年的總股東回報爲124%,而每股收益在過去三年下降了7.3%
Performance at CorMedix Inc. (NASDAQ:CRMD) has been reasonably good and CEO Joe Todisco has done a decent job of steering the company in the right direction. As shareholders go into the upcoming AGM on 21st of November, CEO compensation will probably not be their focus, but rather the steps management will take to continue the growth momentum. Based on our analysis of the data below, we think CEO compensation seems reasonable for now.
CorMedix Inc.(納斯達克:CRMD)的表現相當不錯,首席執行官喬·託迪斯科在引導公司朝着正確方向發展方面做得很好。在即將於11月21日舉行的股東大會上,股東們可能不會將首席執行官的薪酬作爲焦點,而是關注管理層將採取的措施以繼續保持增長勢頭。根據我們對以下數據的分析,我們認爲首席執行官的薪酬目前來看合理。
How Does Total Compensation For Joe Todisco Compare With Other Companies In The Industry?
喬·託迪斯科的總薪酬與行業內其他公司的對比如何?
According to our data, CorMedix Inc. has a market capitalization of US$708m, and paid its CEO total annual compensation worth US$2.5m over the year to December 2023. That's a notable decrease of 15% on last year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$617k.
根據我們的數據,CorMedix Inc. 的市值爲70800萬美元,支付給其首席執行官的年度總薪酬爲250萬美元,截止於2023年12月。這比去年下降了15%。我們認爲總薪酬更爲重要,但我們的數據顯示首席執行官的工資較低,爲61.7萬美元。
For comparison, other companies in the American Pharmaceuticals industry with market capitalizations ranging between US$400m and US$1.6b had a median total CEO compensation of US$2.9m. This suggests that CorMedix remunerates its CEO largely in line with the industry average. Moreover, Joe Todisco also holds US$2.1m worth of CorMedix stock directly under their own name, which reveals to us that they have a significant personal stake in the company.
作爲對比,市值在40000萬至16億之間的其他美國製藥行業公司,首席執行官的中位數總薪酬爲290萬美元。這表明CorMedix在薪酬方面基本與行業平均水平保持一致。此外,喬·託迪斯科還持有價值210萬美元的CorMedix股票,表明他們在公司中有着重要的個人利益。
Component | 2023 | 2022 | Proportion (2023) |
Salary | US$617k | US$378k | 25% |
Other | US$1.8m | US$2.5m | 75% |
Total Compensation | US$2.5m | US$2.9m | 100% |
組成部分 | 2023 | 2022 | 比例(2023) |
薪資 | 617,000美元 | 378,000美元 | 25% |
其他 | 180萬美元 | 2.5百萬美元 | 75% |
總補償 | US$250萬 | US$2.9萬 | 100% |
On an industry level, around 28% of total compensation represents salary and 72% is other remuneration. CorMedix is largely mirroring the industry average when it comes to the share a salary enjoys in overall compensation. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.
在行業板塊層面,約28%的總薪酬爲工資,72%爲其他報酬。 cormedix在工資在整體薪酬中所佔比例方面基本上與行業平均水平相符。如果非工資報酬佔總薪酬的主導地位,這表明高管的工資與公司績效掛鉤。
A Look at CorMedix Inc.'s Growth Numbers
CorMedix Inc.的增長數據回顧
Over the last three years, CorMedix Inc. has shrunk its earnings per share by 7.3% per year. Its revenue is up 41,184% over the last year.
在過去三年中,CorMedix Inc.的每股收益每年下降7.3%。其營業收入在過去一年中增長了41,184%。
Investors would be a bit wary of companies that have lower EPS But on the other hand, revenue growth is strong, suggesting a brighter future. It's hard to reach a conclusion about business performance right now. This may be one to watch. Moving away from current form for a second, it could be important to check this free visual depiction of what analysts expect for the future.
投資者可能會對每股收益較低的公司有所警惕,但另一方面,營業收入增長強勁,暗示着更光明的未來。目前很難對業務表現得出結論。這可能值得關注。暫時離開當前形態,檢查一下分析師對未來的免費可視化預測可能很重要。
Has CorMedix Inc. Been A Good Investment?
CorMedix Inc.是一項好的投資嗎?
We think that the total shareholder return of 124%, over three years, would leave most CorMedix Inc. shareholders smiling. As a result, some may believe the CEO should be paid more than is normal for companies of similar size.
我們認爲,三年來124%的總股東回報將使大多數CorMedix Inc.的股東感到滿意。因此,有些人可能認爲CEO的薪酬應該高於相同規模公司的正常水平。
In Summary...
總之……
Some shareholders will be pleased by the relatively good results, however, the results could still be improved. Despite robust revenue growth, until EPS growth improves, shareholders may be hesitant to increase CEO pay by too much.
一些股東會對相對良好的業績感到滿意,但業績仍有提升空間。儘管營業收入增長強勁,直到每股收益增長改善之前,股東可能對大幅增加CEO薪酬持謹慎態度。
While CEO pay is an important factor to be aware of, there are other areas that investors should be mindful of as well. We did our research and spotted 3 warning signs for CorMedix that investors should look into moving forward.
雖然CEO薪酬是一個需要關注的重要因素,但投資者還應該注意其他方面。我們做了研究,發現CorMedix有3個警示信號,投資者今後應該關注這些。
Switching gears from CorMedix, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.
從CorMedix轉移話題,如果你在尋找優質資產負債表和優厚回報,這份免費的高回報、低債務公司的名單是一個很好的選擇。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
譯文內容由第三人軟體翻譯。